Genomed

Genomed Assets per Share

The Total Assets per Share of Genomed (GEN.WA) as of Oct 30, 2026 is 12.52 PLN. In the previous year, Total Assets per Share was 9.39 PLN — a change of 33.30% (higher).

Assets per Share

12.52PLN

YoY

33.30%

Last updated:

Total Assets per Share of Genomed is 2025 12.52 PLN. Total Assets per Share of Genomed was 2024 9.39 PLN. It decreases by 33.30% higher compared to the previous year.

The Genomed Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
7.05 PLN
Jan 1, 2019
6.79 PLN
Jan 1, 2020
7.58 PLN
Jan 1, 2021
7.82 PLN
Jan 1, 2022
7.86 PLN
Jan 1, 2023
9.18 PLN
Jan 1, 2024
9.39 PLN
Jan 1, 2025
12.52 PLN
The Genomed Assets per Share history
YEARAssets per ShareYoY
12.52PLN+33.30%
9.39PLN+2.29%
9.18PLN+16.81%
7.86PLN+0.46%
7.82PLN+3.19%
7.58PLN+11.72%
6.79PLN-3.70%
7.05PLN+8.66%
6.49PLN+22.59%
5.29PLN+13.23%
4.67PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomed Stock analysis

What does Genomed do? Genomed SA generates revenue through molecular diagnostics services based on DNA sequencing, particularly Next Generation Sequencing (NGS). The company offers gene mutation analysis for over 150 congenital diseases including infertility, cancer predisposition, cystic fibrosis, Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy, and obesity. Their primary clients are healthcare providers and research institutions seeking personalized medicine solutions and genomic technology integration. Genomed SA also provides DNA sequencing, analysis, and synthesis services for the biotechnological market, targeting academic and industrial research sectors. The company's business model focuses on developing advanced diagnostic tools for medical applications, with a strong emphasis on NGS technology. Their service portfolio includes specialized genetic testing for congenital conditions and research-oriented DNA services. By concentrating on personalized medicine and gene treatment clinics, Genomed SA positions itself as a provider of specialized genomic solutions for both clinical and research markets. Genomed SA's revenue streams are derived from diagnostic testing services for congenital diseases and biotechnological DNA services. The company serves healthcare facilities requiring genetic analysis for patient care and research organizations needing genomic data for scientific advancement. Their offerings target medical professionals and biotechnology companies seeking to implement genomic technology in their operations. Genomed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomed stock

Total Assets per Share of Genomed is 12.52 PLN in 2025.

Total Assets per Share of Genomed changed from 9.39 PLN to 12.52 PLN, representing a 33.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Genomed since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Genomed

All Key Metrics — Genomed